System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Christophe Bureau is an expert in Hepatology at Centre Hospitalier Universitaire de Toulouse (France). As of October 2026, ScienceLeadR ranks Christophe Bureau in the top 1% of experts worldwide for Peritonitis, MASH and Hypertension. Christophe Bureau has authored 358 publications, the most recent in 2026, and is an investigator in 42 clinical trials, 14 of them ongoing. SLR score: 1,890 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Christophe Bureau Centre Hospitalier Universitaire de Toulouse France
1 890 ScienceLeadR Reputation 1890

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Cardiology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Toulouse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 358

Citations

Citations: 19 306 1st author: 30 Last author: 47 Unique author: 3

Main journals

J Hepatol 109
Clin Res Hepatol Gastroenterol 33
Hepatology 23
Liver Int 17
Gastroenterol Clin Biol 10

Best Journals

J Hepatol 28
N Engl J Med 5
Lancet Gastroenterol Hepatol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pre-liver transplant assessment of patients with acute-on-chronic liver failure: An international survey.
PMID 42391791 — research design, liver transplantation, acute-on-chronic liver failure, stress, physiological, ear, angiography, liver, transplants, intensive care units, outpatients, nose, pharynx, colonoscopy, liver failure		JHEP Rep20260
Pre-TIPS Liver and Spleen Volumetry Are Not Associated With Liver-Related Outcomes After TIPS Placement for Refractory Ascites.
PMID 42274093 — liver transplantation, portasystemic shunt, transjugular intrahepatic, liver, hypertension, portal, transplants, spleen, ascites		Liver Int20260
Beyond glue injection: rethinking strategy in gastric variceal bleeding.
PMID 42167211 — injections, hemorrhage, endoscopy		Endoscopy20260
Interobserver agreement in the assessment of active bleeding at endoscopy in patients with cirrhosis and acute variceal bleeding.
PMID 42036278 — hemorrhage, endoscopy		Dig Liver Dis20260
Prognostic value of factor VIII, D-dimer and high molecular risk variants assessing re-thrombosis risk in non-cirrhotic portal vein thrombosis.
PMID 41990577 — factor viii, incidence, portal vein, biomarkers, thrombosis, veins		JHEP Rep20260

Clinical Studies 42

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8

By phase:

N/A 17
Phase 3 16
Phase 2 8
Phase 2/Phase 3 1

By status:

Completed 16
Recruiting 9
Terminated 6
Active not recruiting 5
Not yet recruiting 4
Unknown 2

By type:

Interventional 37
Observational 5

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 2
multicentric5to9 4
multicentricup10 30

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH)
2024-512895-36-00 — safety, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
Efficacy and safety of vamifeport in adult subjects with HFE related hereditary hemochromatosis
2025-523793-16-00 — genes, safety, double-blind method, hemochromatosis, genes, regulator		Phase 2Recruiting2026
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
The MAI FOIE Cohort
NCT07594990 — liver diseases, liver, biomarkers		N/ANot yet recruiting2026
An Open label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets
2024-514292-18-00 — cholangitis, tablets, cholangitis, sclerosing		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS